Skip to main content
Erschienen in: Infection 1/2013

01.02.2013 | Clinical and Epidemiological Study

Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study

verfasst von: G. B. Orsi, A. Bencardino, A. Vena, A. Carattoli, C. Venditti, M. Falcone, A. Giordano, M. Venditti

Erschienen in: Infection | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

In the 1,200-bed university hospital “Umberto I” in Rome, Italy, we observed a dramatic substitution of a precedingly well-documented Klebsiella pneumoniae clone (ST37) with ertapenem resistance by outer membrane permeability modification (Porin-ER-Kp) with a new K. pneumoniae strain expressing carbapenem resistance due to K. pneumoniae carbapenemase production (KPC-CR-Kp). A case–case–control study was carried out to evaluate risk factors for Porin-ER-Kp and KPC-CR-Kp isolation.

Methods

All patients with hospital-acquired K. pneumoniae isolation between July 2008 and June 2011 were included. Two case groups including patients harbouring KPC-CR-Kp and Porin-ER-Kp were analysed, with a third control group from whom carbapenem-susceptible K. pneumoniae (CS-Kp) were isolated.

Results

Forty-four KPC-CR-Kp cases, 39 Porin-ER-Kp cases and 60 CS-Kp controls were analysed. During the 3-year study, a specific Porin-ER-Kp endemic clone (ST37) was substituted by a new KPC-CR-Kp clone (ST512). Breakthrough bacteraemias occurred in 21 out of 26 KPC-CR-Kp group bloodstream infections (BSIs); nine of these developed during carbapenem therapy and seven with colistin and/or tigecycline therapy. In 13 Porin-ER-Kp BSIs, breakthrough bacteraemias developed in eight patients and four during carbapenem therapy. In the multivariable analysis, KPC-CR-Kp isolates were associated with carbapenems [odds ratio (OR) 7.74; 95 % confidence interval (CI) 1.70–35.2; p < 0.01) and endoscopy (OR 6.71; 95 % CI 1.25–36.0; p < 0.03). Porin-ER-Kp independent risk factors included second-generation cephalosporins (OR 25.7; 95 % CI 3.20–206.8; p < 0.01), carbapenems (OR 19.1; 95 % CI 4.34–83.9; p < 0.001), acute renal failure (OR 7.17; 95 % CI 1.33–38.6; p < 0.03), endoscopy (OR 6.12; 95 % CI 1.46–25.6; p < 0.02) and third-generation cephalosporins (OR 5.3; 95 % CI 1.34–20.9; p < 0.02).

Conclusions

Porin-ER-Kp strains needed major antimicrobial pressure compared to KPC-CR-Kp to express resistance. KPC-CR-Kp substituted Porin-ER-Kp strains, causing more infections. KPC-CR-Kp breakthrough bacteraemia occurred even under therapy with tigecycline or colistin, underlining that an antibiotic stewardship programme is needed urgently.
Literatur
2.
Zurück zum Zitat Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol. 2010;31:528–31.PubMedCrossRef Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol. 2010;31:528–31.PubMedCrossRef
3.
Zurück zum Zitat Orsi GB, Falcone M, Venditti M. Surveillance and management of multidrug-resistant microorganisms. Expert Rev Anti Infect Ther. 2011;9:653–79.PubMedCrossRef Orsi GB, Falcone M, Venditti M. Surveillance and management of multidrug-resistant microorganisms. Expert Rev Anti Infect Ther. 2011;9:653–79.PubMedCrossRef
4.
Zurück zum Zitat Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.PubMedCrossRef Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.PubMedCrossRef
5.
Zurück zum Zitat Elliott E, Brink AJ, van Greune J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis. 2006;42:e95–8.PubMedCrossRef Elliott E, Brink AJ, van Greune J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis. 2006;42:e95–8.PubMedCrossRef
6.
Zurück zum Zitat Gröbner S, Linke D, Schütz W, et al. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany. J Med Microbiol. 2009;58:912–22.PubMedCrossRef Gröbner S, Linke D, Schütz W, et al. Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany. J Med Microbiol. 2009;58:912–22.PubMedCrossRef
7.
Zurück zum Zitat Leavitt A, Chmelnitsky I, Colodner R, Ofek I, Carmeli Y, Navon-Venezia S. Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol. 2009;47:969–74.PubMedCrossRef Leavitt A, Chmelnitsky I, Colodner R, Ofek I, Carmeli Y, Navon-Venezia S. Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol. 2009;47:969–74.PubMedCrossRef
8.
Zurück zum Zitat Mena A, Plasencia V, García L, et al. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol. 2006;44:2831–7.PubMedCrossRef Mena A, Plasencia V, García L, et al. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol. 2006;44:2831–7.PubMedCrossRef
9.
Zurück zum Zitat Doménech-Sánchez A, Martínez-Martínez L, Hernández-Allés S, et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother. 2003;47:3332–5.PubMedCrossRef Doménech-Sánchez A, Martínez-Martínez L, Hernández-Allés S, et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother. 2003;47:3332–5.PubMedCrossRef
10.
Zurück zum Zitat Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother. 2009;63:659–67.PubMedCrossRef Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother. 2009;63:659–67.PubMedCrossRef
11.
Zurück zum Zitat Jacoby GA, Mills DM, Chow N. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:3203–6.PubMedCrossRef Jacoby GA, Mills DM, Chow N. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:3203–6.PubMedCrossRef
12.
Zurück zum Zitat Wang XD, Cai JC, Zhou HW, Zhang R, Chen GX. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. J Med Microbiol. 2009;58:1196–202.PubMedCrossRef Wang XD, Cai JC, Zhou HW, Zhang R, Chen GX. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. J Med Microbiol. 2009;58:1196–202.PubMedCrossRef
13.
Zurück zum Zitat García-Fernández A, Miriagou V, Papagiannitsis CC, et al. An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob Agents Chemother. 2010;54:4178–84.PubMedCrossRef García-Fernández A, Miriagou V, Papagiannitsis CC, et al. An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob Agents Chemother. 2010;54:4178–84.PubMedCrossRef
14.
Zurück zum Zitat Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54–60.PubMedCrossRef Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54–60.PubMedCrossRef
15.
Zurück zum Zitat Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124–30.PubMedCrossRef Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124–30.PubMedCrossRef
16.
Zurück zum Zitat Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5.PubMedCrossRef Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5.PubMedCrossRef
17.
Zurück zum Zitat Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010;31:1242–9.PubMedCrossRef Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010;31:1242–9.PubMedCrossRef
18.
Zurück zum Zitat Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–71.PubMedCrossRef Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–71.PubMedCrossRef
19.
Zurück zum Zitat Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31:1250–6.PubMedCrossRef Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31:1250–6.PubMedCrossRef
20.
Zurück zum Zitat Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106.PubMedCrossRef Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106.PubMedCrossRef
21.
Zurück zum Zitat Orsi GB, García-Fernández A, Giordano A, et al. Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients. J Hosp Infect. 2011;78:54–8.PubMedCrossRef Orsi GB, García-Fernández A, Giordano A, et al. Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients. J Hosp Infect. 2011;78:54–8.PubMedCrossRef
22.
Zurück zum Zitat Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. In: Olmsted RN, editor. APIC infection control and applied epidemiology: principles and practice. St. Louis: Mosby; 1996: p. A1–20. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. In: Olmsted RN, editor. APIC infection control and applied epidemiology: principles and practice. St. Louis: Mosby; 1996: p. A1–20.
23.
Zurück zum Zitat Bryan CS. Clinical implications of positive blood cultures. Clin Microbiol Rev. 1989;2:329–53.PubMed Bryan CS. Clinical implications of positive blood cultures. Clin Microbiol Rev. 1989;2:329–53.PubMed
24.
Zurück zum Zitat Tsakris A, Poulou A, Pournaras S, et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010;65:1664–71.PubMedCrossRef Tsakris A, Poulou A, Pournaras S, et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010;65:1664–71.PubMedCrossRef
25.
Zurück zum Zitat Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43:4178–82.PubMedCrossRef Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43:4178–82.PubMedCrossRef
26.
Zurück zum Zitat Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case–control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001;32:1055–61.PubMedCrossRef Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case–control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001;32:1055–61.PubMedCrossRef
27.
Zurück zum Zitat Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK; Centers for Disease Control and Prevention Epicenter Program. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2011;53:532–40.PubMedCrossRef Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK; Centers for Disease Control and Prevention Epicenter Program. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2011;53:532–40.PubMedCrossRef
28.
Zurück zum Zitat Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy. 39th ed. Sperryville: Antimicrobial Therapy, Inc.; 2009. Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy. 39th ed. Sperryville: Antimicrobial Therapy, Inc.; 2009.
29.
Zurück zum Zitat Tsai YK, Fung CP, Lin JC, et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother. 2011;55:1485–93.PubMedCrossRef Tsai YK, Fung CP, Lin JC, et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother. 2011;55:1485–93.PubMedCrossRef
30.
Zurück zum Zitat Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay. Int J Antimicrob Agents. 2011;37:244–7.PubMedCrossRef Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay. Int J Antimicrob Agents. 2011;37:244–7.PubMedCrossRef
31.
Zurück zum Zitat Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis. 2010;67:180–4.PubMedCrossRef Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis. 2010;67:180–4.PubMedCrossRef
32.
Zurück zum Zitat Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.PubMedCrossRef Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.PubMedCrossRef
33.
Zurück zum Zitat Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53:1868–73.PubMedCrossRef Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53:1868–73.PubMedCrossRef
Metadaten
Titel
Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study
verfasst von
G. B. Orsi
A. Bencardino
A. Vena
A. Carattoli
C. Venditti
M. Falcone
A. Giordano
M. Venditti
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 1/2013
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0354-2

Weitere Artikel der Ausgabe 1/2013

Infection 1/2013 Zur Ausgabe

Images in Infection

Spinal cord toxoplasmosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.